Nykode Therapeutics ASA (NYKD) - Net Assets
Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has net assets worth Nkr1.05 Billion NOK (≈ $110.32 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr1.05 Billion ≈ $111.00 Million USD) and total liabilities (Nkr6.45 Million ≈ $678.20K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Nykode Therapeutics ASA to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr1.05 Billion |
| % of Total Assets | 99.39% |
| Annual Growth Rate | 24.77% |
| 5-Year Change | -23.84% |
| 10-Year Change | N/A |
| Growth Volatility | 259.45 |
Nykode Therapeutics ASA - Net Assets Trend (2016–2024)
This chart illustrates how Nykode Therapeutics ASA's net assets have evolved over time, based on quarterly financial data. Also explore NYKD asset base for the complete picture of this company's asset base.
Annual Net Assets for Nykode Therapeutics ASA (2016–2024)
The table below shows the annual net assets of Nykode Therapeutics ASA from 2016 to 2024. For live valuation and market cap data, see Nykode Therapeutics ASA (NYKD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr136.21 Million ≈ $14.33 Million |
-20.46% |
| 2023-12-31 | Nkr171.26 Million ≈ $18.02 Million |
+9.07% |
| 2022-12-31 | Nkr157.02 Million ≈ $16.52 Million |
-19.09% |
| 2021-12-31 | Nkr194.06 Million ≈ $20.42 Million |
+8.50% |
| 2020-12-31 | Nkr178.85 Million ≈ $18.82 Million |
-26.27% |
| 2019-12-31 | Nkr242.56 Million ≈ $25.52 Million |
+73.17% |
| 2018-12-31 | Nkr140.07 Million ≈ $14.74 Million |
-31.18% |
| 2017-12-31 | Nkr203.53 Million ≈ $21.42 Million |
+777.80% |
| 2016-12-31 | Nkr23.19 Million ≈ $2.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nykode Therapeutics ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 332533200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr367.00K | 0.27% |
| Other Components | Nkr144.61 Million | 106.16% |
| Total Equity | Nkr136.21 Million | 100.00% |
Nykode Therapeutics ASA Competitors by Market Cap
The table below lists competitors of Nykode Therapeutics ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yuken India Limited
NSE:YUKEN
|
$110.88 Million |
|
Currency Exchange International Corp
TO:CXI
|
$110.89 Million |
|
Action Electronics Co Ltd
TW:3024
|
$110.90 Million |
|
Thuan Duc JSC
VN:TDP
|
$110.99 Million |
|
Wielton S.A.
WAR:WLT
|
$110.77 Million |
|
Ramaco Resources Inc.
NASDAQ:METCB
|
$110.76 Million |
|
Edel SE & Co. KGaA
F:EDL
|
$110.59 Million |
|
Crosswood
PA:CROS
|
$110.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nykode Therapeutics ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 171,259,000 to 136,214,000, a change of -35,045,000 (-20.5%).
- Net loss of 38,821,000 reduced equity.
- Other factors increased equity by 3,776,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-38.82 Million | -28.5% |
| Other Changes | Nkr3.78 Million | +2.77% |
| Total Change | Nkr- | -20.46% |
Book Value vs Market Value Analysis
This analysis compares Nykode Therapeutics ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.76x to 7.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr0.42 | Nkr3.23 | x |
| 2017-12-31 | Nkr0.84 | Nkr3.23 | x |
| 2018-12-31 | Nkr0.58 | Nkr3.23 | x |
| 2019-12-31 | Nkr0.83 | Nkr3.23 | x |
| 2020-12-31 | Nkr0.61 | Nkr3.23 | x |
| 2021-12-31 | Nkr0.73 | Nkr3.23 | x |
| 2022-12-31 | Nkr0.52 | Nkr3.23 | x |
| 2023-12-31 | Nkr0.57 | Nkr3.23 | x |
| 2024-12-31 | Nkr0.42 | Nkr3.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nykode Therapeutics ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -447.30%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.13x
- Recent ROE (-28.50%) is below the historical average (-12.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -6.92% | -6674.84% | 0.00x | 1.08x | Nkr-3.92 Million |
| 2017 | -15.41% | -321.31% | 0.05x | 1.05x | Nkr-51.72 Million |
| 2018 | -45.54% | -529.75% | 0.08x | 1.09x | Nkr-77.80 Million |
| 2019 | -49.57% | -969.97% | 0.04x | 1.21x | Nkr-144.49 Million |
| 2020 | 83.74% | 69.66% | 0.93x | 1.29x | Nkr131.89 Million |
| 2021 | -4.85% | -27.72% | 0.13x | 1.37x | Nkr-28.82 Million |
| 2022 | -27.22% | -596.30% | 0.03x | 1.41x | Nkr-58.44 Million |
| 2023 | -20.53% | -272.47% | 0.06x | 1.22x | Nkr-52.28 Million |
| 2024 | -28.50% | -447.30% | 0.06x | 1.13x | Nkr-52.44 Million |
Industry Comparison
This section compares Nykode Therapeutics ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $83,458,983
- Average return on equity (ROE) among peers: -104.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nykode Therapeutics ASA (NYKD) | Nkr1.05 Billion | -6.92% | 0.01x | $110.82 Million |
| Arcticzymes Technologies ASA (AZT) | $61.15 Million | -162.49% | 0.51x | $117.69 Million |
| Bergenbio ASA (BGBIO) | $12.05 Million | 0.00% | 0.48x | $7.75 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $146.68 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $9.59 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $80.92 Million |
| Oncoinvent ASA (ONCIN) | $146.33 Million | -105.98% | 0.40x | $23.00 Million |
| PCI Biotech Holding ASA (PCIB) | $339.95 Million | -10.23% | 0.05x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $76.22 Million | -49.08% | 0.15x | $28.83 Million |
| Thor Medical ASA (TRMED) | $63.84 Million | -487.52% | 0.72x | $164.94 Million |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more